Superior protein quality control in a user-friendly format

Article

The Agilent 2100 Bioanalyzer plus the Agilent High Sensitivity Protein 250 Kit automatically detects and quantifies protein impurities down to 0.05% for superior Protein QC in a production-ready method!

The Agilent 2100 Bioanalyzer together with the Agilent High Sensitivity Protein 250 Kit offers unsurpassed speed, sensitivity and reproducibility for superior protein QC in a production-ready method. It detects and quantifies low concentrated impurities next to massive main components – down to 0.05% and below. This meets the ICH guideline Q3B(R2) on Impurities in New Drug Products!

Built on Agilent’s industry leading lab-on-a-chip platform, the 2100 Bioanalyzer offers:

  • Sensitivity and linear dynamic range – silver stain sensitivity down to 1 pg/μL of labeled protein on chip and 4 orders of magnitude in linear dynamic range.
  • Fast results – complete automated analysis of 10 samples in 30 minutes.
  • Reproducibility — qualitative, user-independent and digital data.
  • Ease of use — standardized assay, pre-packaged reagent kits.
  • 21 CFR Part 11 compliance — validated reagents, software, and compliance services to meet all GMP/GLP needs.

The High Sensitivity Protein 250 kit provides the first microfluidic assay for protein detection in the low picogram range. Therefore, the kit is perfectly suited to solve typical protein QA/QC questions and to comply with ICH and FDA guidelines.

Learn more about the Agilent 2100 Bioanalyzer.
Request Agilent’s Protein QC Application CD!

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content